Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
Clotblog with Dr Samuel Goldhaber
View all posts »LIFENOX: No advantage of VTE prophylaxis in hospitalized medical service patients
Jan 13, 2012 09:20 EST-
1Comments
-
Read later
The surprising results of the LIFENOX trial—which failed to show an advantage of daily enoxaparin vs placebo to reduce mortality in the acute-care setting—challenge dogma. What explains these results?
See also:
Kakkar AK, Cimminiello C, Goldhaber SZ, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2012; 365:2463-2472. Abstract.
Enoxaparin prophylaxis doesn't cut mortality in acute-care setting
Your comments
 |
 |
 |
||
 |
|
 |
||
 |
 |
 |
||
 |
|
|
 |
|
 |
 |
 |
||
 |
|
|
 |
|
|
|
|
||
|
||||
You must be a member (with full membership) to post a comment.
Already a member?
Enjoy all the benefits of theheart.org
With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.
Membership is free!
